SNAP-CAR represents a major advance
potentially expanding the targeting capabilities of chimeric
antigen receptor (CAR) T cells for various cancers and other
indications
WEXFORD,
Pa., May 10, 2023 /PRNewswire/ -- Coeptis
Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the
Company"), a biopharmaceutical company developing innovative cell
therapy platforms for cancer, announced that research involving its
SNAP-CAR technology was detailed in a peer-reviewed article
published in the peer-reviewed journal, Nature
Communications. SNAP-CAR is a multi-antigen chimeric antigen
receptor T cell (CAR T) technology that can be adapted to different
cancer indications, including hematologic and solid
tumors.
The article titled, "Post-translational covalent assembly of CAR
and synNotch receptors for programmable antigen targeting,"
describes key advances in antigen receptor design to develop
"universal" receptor systems for diverse programming of cell
behaviors using covalent chemistry. Using in vitro and in
vivo models, the authors demonstrated that the SNAP-CAR
platform provides a powerful adaptor strategy for fully
programmable targeting of engineered cells to multiple antigens.
Further, it was concluded that these systems have the potential for
clinical application and biotechnological utility by providing
researchers with the ability to rapidly screen CAR and synNotch
antibody candidates and to rewire and activate cellular programs in
response to highly specific antibody-antigen interactions.
"This research highlights key advances in antigen receptor
design, including the creation of a universal adaptor synNotch
system and a universal CAR system that act through self-labeling
enzyme chemistry, representing a potential breakthrough in
programmable antigen targeting," said Jason
Lohmueller, Ph.D., Assistant Professor of Surgery and
Immunology in the Division of Surgical Oncology Research,
University of Pittsburgh. "These
'universal' receptor systems, for which receptor specificity can be
directed post-translationally via covalent attachment of a
co-administered antibody, offer the potential to allow for one
population of T cells to target multiple tumor antigens, enabling
the development of cell therapies for a wide range of cancers,
including hematologic and solid tumors."
"SNAP-CAR represents a powerful technology with the potential to
be engineered to address numerous cancers, including
HER2-expressing cancer, which we are targeting as our potential
first-in-human clinical development program," said Dave Mehalick, President and CEO of Coeptis
Therapeutics. "Having research on SNAP-CAR published in such a
prestigious scientific journal as Nature Communications
provides further validation of the technology's potential and the
groundbreaking work being conducted by Dr. Lohmueller and his team
at the University of Pittsburgh."
About SNAP-CAR
SNAP-CAR, which Coeptis Therapeutics
licensed from the University of
Pittsburgh, is designed to be a "universal" CAR T cell
therapy platform that can be adapted to different cancer
indications. Instead of directly binding to a target on the tumor
cell, CAR T cells are co-administered with one or more antibody
adaptors that bind to the tumor cells and are fitted with a
chemical group that irreversibly connects them to the SNAP-CAR on
the therapeutic cells via a covalent bond. Pre-clinical studies in
mice have demonstrated that by targeting tumors via antibody
adaptor molecules, the SNAP-CAR therapy provides a highly
programmable therapeutic platform.
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its
subsidiaries including Coeptis Therapeutics,
Inc. and Coeptis Pharmaceuticals,
Inc., (collectively "Coeptis"), is a biopharmaceutical
company developing innovative cell therapy platforms for cancer
that have the potential to disrupt conventional treatment paradigms
and improve patient outcomes. Coeptis' product portfolio and rights
are highlighted by assets from Deverra Therapeutics including an
allogeneic stem cell platform and DVX201, an unmodified natural
killer (NK) cell therapy in Phase 1 clinical trials, a universal,
multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and
intellectual property and knowhow related the GEAR™ cell therapy
and companion diagnostic platforms, which Coeptis is
developing with VyGen-Bio and leading medical researchers at
the Karolinska Institutet. Coeptis' business model is designed
around maximizing the value of its current product portfolio and
rights through in-license agreements, out-license agreements and
co-development relationships, as well as entering into strategic
partnerships to expand its product rights and offerings,
specifically those targeting cancer. The Company is headquartered
in Wexford, PA. For more information on Coeptis
visit https://coeptistx.com/.
Cautionary Note Regarding Forward-Looking
Statements
This press release and statements of our management made in
connection therewith contain or may contain "forward-looking
statements" (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended). Forward-looking statements include statements
concerning our plans, objectives, goals, strategies, future events
or performance, and underlying assumptions, and other statements
that are other than statements of historical facts. When we use
words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar
expressions that do not relate solely to historical matters, we are
making forward-looking statements. Forward-looking statements are
not a guarantee of future performance and involve significant risks
and uncertainties that may cause the actual results to differ
materially and perhaps substantially from our expectations
discussed in the forward-looking statements. Factors that may cause
such differences include but are not limited to: (1) the inability
to maintain the listing of the Company's securities on the Nasdaq
Global Market following the business combination; (2) the risk that
the business combination disrupts current plans and operations of
Company as a result of the consummation of the business
combination; (3) the inability to recognize the anticipated
benefits of the business combination, which may be affected by,
among other things, competition, the ability of the Company to grow
and manage growth economically and hire and retain key employees;
(4) the risks that the Company's products in development fail
clinical trials or are not approved by the U.S. Food and Drug
Administration or other applicable regulatory authorities; (5)
costs related to the business combination; (6) changes in
applicable laws or regulations; (7) the possibility that the
Company may be adversely affected by other economic, business,
and/or competitive factors; and (8) the impact of the global
COVID-19 pandemic on any of the foregoing risks and other risks and
uncertainties identified in the Company's filings with the
Securities and Exchange Commission (the "SEC"). The foregoing list
of factors is not exclusive. All forward-looking statements are
subject to significant uncertainties and risks including, but not
limited, to those risks contained or to be contained in reports and
other filings filed by the Company with the SEC. For these reasons,
among others, investors are cautioned not to place undue reliance
upon any forward-looking statements in this press release.
Additional factors are discussed in the Company's filings made or
to be made with the SEC, which are available for review
at www.sec.gov. We undertake no obligation to publicly revise these
forward-looking statements to reflect events or circumstances that
arise after the date hereof unless required by applicable laws,
regulations, or rules.
CONTACTS
Coeptis Therapeutics, Inc.
Andy Galy, Sr. VP of Communications
504-416-6965
andy.galy@coeptistx.com
Tiberend Strategic Advisors, Inc.
Investors
Jon Nugent
205-566-3026
jnugent@tiberend.com
Media
David
Schemelia
609-468-9325
dschemelia@tiberend.com
View original
content:https://www.prnewswire.com/news-releases/coeptis-therapeutics-snap-car-technology-platform-for-programmable-antigen-targeting-featured-in-peer-reviewed-article-in-nature-communications-301821267.html
SOURCE Coeptis